Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Volume 6, Issue 1
  5. Article
Volume 6, Issue 1
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

After the COVID-19 pandemic, the world has been vulnerable due to another virus called monkeypox. Monkeypox is a very uncommon zoonotic infectious condition that occurs in both human and non-human primates with similar clinical characteristics as smallpox along with remarkable epidemic potential because of the increasing existence of human outbursts in recent scenarios. The increasing number of cases of this virus is developing curiosity among the people, hence scientists are aiming to become aware of various pathological characteristics and management of this virus before it becomes an epidemic. Currently, the monkeypox outbreak is a trending headline and has increased as an alarming tone after continuous upcoming cases. Previous studies revealed that the first human suspected case was found on September 1, 1970, when a 9-month-old baby was admitted to the Basankusu Hospital in the Democratic Republic of Congo. It is hard to distinguish monkeypox from the smallpox virus therefore, laboratory testing is the technique of disease identification and monitoring. Various new approaches and vaccines are being positioned for the prevention and clinical management of monkeypox through the entanglement of metallic and organic nanocarriers. However, more researchers suggested that virology and ecology of the virus in endemic areas is essential to recognize and avoid further worldwide occurrence of this virus. On behalf of an exhaustive literature survey, We are providing a rationalizing overview of monkeypox in the context of its present global outbreak, as well as its symptoms, prevention, treatment, assessment, and clinical studies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975274137240222091059
2024-02-29
2025-01-06

  • From This Site

    /content/journals/covid/10.2174/0126667975274137240222091059
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LadnyjI.D. ZieglerP. KimaE. A human infection caused by monkeypox virus in basankusu territory, democratic republic of the congo.Bull. World Health Organ.1972465593597 4340218
     [Google Scholar]
  2. HaiderN. GuitianJ. SimonsD. Increased outbreaks of monkeypox highlight gaps in actual disease burden in Sub-Saharan Africa and in animal reservoirs.Int. J. Infect. Dis.202212210711110.1016/j.ijid.2022.05.058 35640830
     [Google Scholar]
  3. Multi-country monkeypox outbreak: Situation update. world health organization.2022Available from: https://www.google.com/search?client=firefox-b-d&q=3.+Multi-country+monkeypox+outbreak%3A+situation+update.+World+Health+Organization
  4. SinghalT. KabraS.K. LodhaR. Monkeypox: A review.Indian J. Pediatr.2022891095596010.1007/s12098‑022‑04348‑0 35947269
     [Google Scholar]
  5. PetersenE. KanteleA. KoopmansM. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention.Infectious Disease Clinics201933410271043 30981594
     [Google Scholar]
  6. IslamMR AsaduzzamanM ShahriarM BhuiyanMA The spreading of monkeypox in nonendemic countries has created panic across the world: could it be another threat? Published online ahead of print.J Med Virol2022202210.1002/jmv.2791935672908
     [Google Scholar]
  7. KalerJ. HussainA. FloresG. KheiriS. DesrosiersD. Monkeypox: A comprehensive review of transmission, pathogenesis, and manifestation.Cureus2022147e2653110.7759/cureus.26531 35928395
     [Google Scholar]
  8. AlakunleE. MoensU. NchindaG. OkekeM.I. Monkeypox virus in Nigeria: Infection biology, epidemiology, and evolution.Viruses20201211125710.3390/v12111257 33167496
     [Google Scholar]
  9. World Health Organization.Multi-country outbreak of monkeypox.2022Available from https://www.google.com/search?client=firefox-b-d&q=9.+World+Health+Organization.+Multi-country+outbreak+of+monkeypox.+World+Health+Organization
    [Google Scholar]
  10. World Health Organization.2022Available from: https://www.afro.who.int/news/who-supporting-african-countries-strengthen-monkeypox-surveillance-and-response-actions
  11. World Health Organization.2022Available from: https://www.who.int/news/item/23-07-2022-second-meeting-of-the-international-health-regulations-(2005)-(ihr)-emergency-committee-regarding-the-multi-country-outbreak-of-monkeypox
  12. BlancoJ.L. FlorenceE. MoscheseD. Monkeypox virus infection in humans across 16 countries–April-June 2022.N. Engl. J. Med.2022
     [Google Scholar]
  13. GuarnerJ. del RioC. MalaniP.N. Monkeypox in 2022—what clinicians need to know.JAMA2022328213914010.1001/jama.2022.10802 35696257
     [Google Scholar]
  14. OkyayRA BayrakE KayaE Another epidemic in the shadow of Covid 19 pandemic: A review of monkeypox.proteins 2022710104744
     [Google Scholar]
  15. LiP. PachisS.T. XuG. Mpox virus infection and drug treatment modelled in human skin organoids.Nat. Microbiol.20238112067207910.1038/s41564‑023‑01489‑6 37828248
     [Google Scholar]
  16. MagnusP. AndersenE.K. PetersenK.B. Birch-AndersenA. A pox‐like disease in cynomolgus monkeys.Acta Pathol. Microbiol. Scand.195946215617610.1111/j.1699‑0463.1959.tb00328.x
     [Google Scholar]
  17. SimpsonK. HeymannD. BrownC.S. Human monkeypox – After 40 years, an unintended consequence of smallpox eradication.Vaccine202038335077508110.1016/j.vaccine.2020.04.062 32417140
     [Google Scholar]
  18. HutsonC.L. OlsonV.A. CarrollD.S. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus.J. Gen. Virol.200990232333310.1099/vir.0.005108‑0 19141441
     [Google Scholar]
  19. HarrisE. What to know about monkeypox.JAMA2022327232278227910.1001/jama.2022.9499 35622356
     [Google Scholar]
  20. Di GiulioD.B. EckburgP.B. Human monkeypox: An emerging zoonosis.Lancet Infect. Dis.200441152510.1016/S1473‑3099(03)00856‑9 14720564
     [Google Scholar]
  21. El EidR. AllawF. HaddadS.F. KanjS.S. Human monkeypox: A review of the literature.PLoS Pathog.2022189e101076810.1371/journal.ppat.1010768 36136979
     [Google Scholar]
  22. HraibM. JouniS. AlbitarM.M. AlaidiS. AlshehabiZ. The outbreak of monkeypox 2022: An overview.Ann. Med. Surg.20227910406910.1016/j.amsu.2022.104069 35860140
     [Google Scholar]
  23. RizkJ.G. LippiG. HenryB.M. ForthalD.N. RizkY. Prevention and treatment of monkeypox.Drugs202282995796310.1007/s40265‑022‑01742‑y 35763248
     [Google Scholar]
  24. AltindisM. PucaE. ShapoL. Diagnosis of monkeypox virus – An overview.Travel Med. Infect. Dis.20225010245910.1016/j.tmaid.2022.102459 36109000
     [Google Scholar]
  25. NakhaieM. ArefiniaN. CharostadJ. BashashD. Haji AbdolvahabM. ZareiM. Monkeypox virus diagnosis and laboratory testing.Rev. Med. Virol.2023331e240410.1002/rmv.2404 36331049
     [Google Scholar]
  26. DuboisM.E. SlifkaM.K. Retrospective analysis of monkeypox infection.Emerg. Infect. Dis.200814459259910.3201/eid1404.071044 18394277
     [Google Scholar]
  27. HermanussenL. GreweI. TangH.T. Tecovirimat therapy for severe monkeypox infection: Longitudinal assessment of viral titers and clinical response pattern—A first case‐series experience.J. Med. Virol.2023951e2818110.1002/jmv.28181 36177717
     [Google Scholar]
  28. SinghL. KrugerH.G. MaguireG.E.M. GovenderT. ParboosingR. The role of nanotechnology in the treatment of viral infections.Ther. Adv. Infect. Dis.20174410513110.1177/2049936117713593 28748089
     [Google Scholar]
  29. PottooF.H. SharmaS. JavedM.N. Lipid-based nanoformulations in the treatment of neurological disorders.Drug Metab. Rev.202052118520410.1080/03602532.2020.1726942 32116044
     [Google Scholar]
  30. BhartiC. AlamM.S. JavedM.N. KhalidM. SaifullahF.A. ManchandaR. Silica based nanomaterial for drug delivery. Nanomaterials.Evolution and Advance Towards Therapeutic Drug Delivery2021Part 25789
     [Google Scholar]
  31. MishraS. SharmaS. JavedM.N. Bioinspired nanocomposites: Applications in disease diagnosis and treatment.Pharm. Nanotechnol.20197320621910.2174/2211738507666190425121509 31030662
     [Google Scholar]
  32. Kumar SethiyaN. GhiloriaN. SrivastavA. Therapeutic Potential of Myricetin in the Treatment of Neurological, Neuropsychiatric, and Neurodegenerative Disorders.CNS Neurol. Disord. Drug Targets2023 37461364
     [Google Scholar]
  33. JavedM.N. AlamM.S. WaziriA. QbD applications for the development of nanopharmaceutical products.In: InPharmaceutical quality by design. Academic Press201922925310.1016/B978‑0‑12‑815799‑2.00013‑7
     [Google Scholar]
  34. JavedMN DahiyaES IbrahimAM AlamMS KhanFA PottooFH Recent advancement in clinical application of nanotechnological approached targeted delivery of herbal drugs.Nanophytomedicine: Concept to Clinic20201517210.1007/978‑981‑15‑4909‑0_9
     [Google Scholar]
  35. JavedM.N. PottooF.H. ShamimA. HasnainM.S. AlamM.S. Design of experiments for the development of nanoparticles, nanomaterials, and nanocomposites.In: Design of Experiments for Pharmaceutical Product Development. Applications and Practical Case studies20211516910.1007/978‑981‑33‑4351‑1_9
     [Google Scholar]
  36. AslamM. JavedM.N. DeebH.H. Lipid carriers mediated targeted delivery of nutraceuticals: Challenges, role of blood brain barrier and promises of nanotechnology based ap-proaches in neuronal disorders.Curr. Drug Metab.2020212110.2174/1389200221999200728143511
     [Google Scholar]
  37. KumariN DaramN AlamMS VermaAK Rationalizing the use of polyphenol nano-formulations in the therapy of neurodegenerative diseases.CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological2022211096676
     [Google Scholar]
  38. JavedM.N. AkhterM.H. TaleuzzamanM. FaiyazudinM. AlamM.S. Cationic nanoparticles for treatment of neurological diseases.In: InFundamentals of Bionanomaterials. Elsevier202227329210.1016/B978‑0‑12‑824147‑9.00010‑8
     [Google Scholar]
  39. Iriarte-MesaC. LópezY.C. Matos-PeraltaY. de la Vega-HernándezK. AntuchM. Gold, silver and iron oxide nanoparticles: Synthesis and bionanoconjugation strategies aimed at electrochemical applications.Top. Curr. Chem.202037811210.1007/s41061‑019‑0275‑y 31907672
     [Google Scholar]
  40. Al-HalifaS. GauthierL. ArpinD. BourgaultS. ArchambaultD. Nanoparticle-based vaccines against respiratory viruses.Front. Immunol.2019102210.3389/fimmu.2019.00022 30733717
     [Google Scholar]
  41. JavedMN PottooFH AlamMS Metallic nanoparticle alone and/or in combination as novel agent for the treatment of uncontrolled electric conductance related disorders and/or seizure, epilepsy & convulsions.Patent acquired on October201640
  42. PanditJ. AlamM.S. AnsariJ.R. Multifaced applications of nanoparticles in biological science InNanomaterials in the Battle Against Pathogens and Disease Vectors.CRC Press20221750
     [Google Scholar]
  43. AlamM.S. NasehM.F. AnsariJ.R. Synthesis approaches for higher yields of nanoparticles InNanomaterials in the Battle Against Pathogens and Disease Vectors.CRC Press20225182
     [Google Scholar]
  44. XiangD. ZhengC. ZhengY. Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo.Int. J. Nanomedicine201384103411310.2147/IJN.S53622 24204140
     [Google Scholar]
  45. GaldieroS. FalangaA. VitielloM. CantisaniM. MarraV. GaldieroM. Silver nanoparticles as potential antiviral agents.Molecules201116108894891810.3390/molecules16108894 22024958
     [Google Scholar]
  46. AlamMS GargA PottooFH Gum ghatti mediated, one pot green synthesis of optimized gold nanoparticles: Investigation of process-variables impact using Box-Behnken based statistical design. Int J Biol Macromol2017104Pt A7586710.1016/j.ijbiomac.2017.05.12928601649
    [Google Scholar]
  47. AlamM.S. JavedM.N. PottooF.H. QbD approached comparison of reaction mechanism in microwave synthesized gold nanoparticles and their superior catalytic role against hazardous nirto‐dye.Appl. Organomet. Chem.2019339e507110.1002/aoc.5071
     [Google Scholar]
  48. Meléndez-VillanuevaM.A. Morán-SantibañezK. Martínez-SanmiguelJ.J. Virucidal activity of gold nanoparticles synthesized by green chemistry using garlic extract.Viruses20191112111110.3390/v11121111 31801280
     [Google Scholar]
  49. RahaS. MallickR. BasakS. DuttaroyA.K. Is copper beneficial for COVID-19 patients?Med. Hypotheses202014210981410.1016/j.mehy.2020.109814 32388476
     [Google Scholar]
  50. RaiM. DeshmukhS.D. IngleA.P. GuptaI.R. GaldieroM. GaldieroS. Metal nanoparticles: The protective nanoshield against virus infection.Crit. Rev. Microbiol.2016421465610.3109/1040841X.2013.879849 24754250
     [Google Scholar]
  51. JiangJ. PiJ. CaiJ. The advancing of zinc oxide nanoparticles for biomedical applications.Bioinorg. Chem. Appl.2018201811810.1155/2018/1062562 30073019
     [Google Scholar]
  52. KrólA. PomastowskiP. RafińskaK. Railean-PlugaruV. BuszewskiB. Zinc oxide nanoparticles: Synthesis, antiseptic activity and toxicity mechanism.Adv. Colloid Interface Sci.2017249375210.1016/j.cis.2017.07.033 28923702
     [Google Scholar]
  53. JanaszewskaA. LazniewskaJ. TrzepińskiP. MarcinkowskaM. Klajnert-MaculewiczB. Cytotoxicity of dendrimers.Biomolecules20199833010.3390/biom9080330 31374911
     [Google Scholar]
  54. ThiagarajanG. RayA. MaluginA. GhandehariH. PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cells.Pharm. Res.201027112307231610.1007/s11095‑010‑0179‑6 20552256
     [Google Scholar]
  55. JiaF. LiuX. LiL. MallapragadaS. NarasimhanB. WangQ. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents.J. Control. Release201317231020103410.1016/j.jconrel.2013.10.012 24140748
     [Google Scholar]
  56. VenkataramanS. HedrickJ.L. OngZ.Y. The effects of polymeric nanostructure shape on drug delivery.Adv. Drug Deliv. Rev.20116314-151228124610.1016/j.addr.2011.06.016 21777633
     [Google Scholar]
  57. ImmordinoM.L. DosioF. CattelL. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.Int. J. Nanomedicine200613297315 17717971
     [Google Scholar]
  58. LiW. WuJ. ZhanP. Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates.Int. J. Biol. Macromol.201250497498010.1016/j.ijbiomac.2012.02.019 22390847
     [Google Scholar]
  59. ChakravartyM. VoraA. Nanotechnology-based antiviral therapeutics.Drug Deliv. Transl. Res.202111374878710.1007/s13346‑020‑00818‑0 32748035
     [Google Scholar]
  60. DiabR. Jaafar-MaalejC. FessiH. MaincentP. Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?AAPS J.201214468870210.1208/s12248‑012‑9377‑y 22767270
     [Google Scholar]
  61. CIDRAPFDA approves VIG for smallpox shot complications Available from: https://www.cidrap.umn.edu/news-perspective/2005/02/fda-approves-vig-smallpox-
    [Google Scholar]
  62. TitanjiBK TegomohB NematollahiS KonomosM KulkarniPA Monkeypox: A contemporary review for healthcare professionals.InOpen forum infectious diseases20229710.1093/ofid/ofac310
     [Google Scholar]
  63. Centers for Disease Control and Prevention.Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol during.2022Available from https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
    [Google Scholar]
  64. US Food and Drug AdministrationFDA approves drug to treat smallpox.2021Available from https://www.fda.gov/drugs/news-events-human-drugs/
    [Google Scholar]
  65. Cohort study of healthcare workers receiving imvanex.NCT037451312021
  66. Phase I Trial of an Investigational Small Pox MedicationNCT007286892021
  67. Break-through Infection Following Monkeypox vaccinatIoNCT055222962021
  68. Study of tecovirimat for human monkeypox virus.NCT055349842021
  69. Smallpox vaccine in adult healthcare personnel at risk for monkeypox in the democratic republic of the congo.NCT029777152021
  70. A one health study of monkeypox human infection.NCT050588982021
/content/journals/covid/10.2174/0126667975274137240222091059
Loading
An Updated Review on the Alarming Epidemic of the Monkeypox Virus
Coronaviruses 6, E290224227546 (2025); https://doi.org/10.2174/0126667975274137240222091059
/content/journals/covid/10.2174/0126667975274137240222091059
/content/journals/covid/10.2174/0126667975274137240222091059
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): clinical trials; COVID-19; endemic; epidemiology; Monkeypox virus; zoonotic infection
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test